

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN INSTITUTIONAL INC.,
Petitioner

v.

FRESENIUS KABI USA, LLC,
Patent Owner.

U.S. Patent No. 9,168,238 to Jiang *et al.*
Issue Date: October 27, 2015
Title: Levothyroxine Formulations

Inter Partes Review No.: IPR2017-00643

**Petition for *Inter Partes* Review of U.S. Patent No. 9,168,238 Under
35 U.S.C. §§ 311-319 and 37 C.F.R. §§ 42.1-.80, 42.100-.123**

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. OVERVIEW	1
III. STANDING (37 C.F.R. § 42.104(a); PROCEDURAL STATEMENTS)	2
IV. MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1))	3
A. Each Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))	3
B. Notice of Related Matters (37 C.F.R. § 42.8(b)(2))	3
1. Judicial Matters	3
2. Administrative Matters	4
C. Designation of Lead and Back-Up Counsel and Service (37 C.F.R. §§ 42.8(b)(3), 42.8(b)(4), 42.10(a), and 42.10(b)):	4
V. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFORE (37 C.F.R. § 42.22(a))	5
VI. THE '238 PATENT	5
A. Claim Construction	5
VII. PERSON OF ORDINARY SKILL IN THE ART & STATE OF THE ART	8
VIII. IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(b))	9
IX. INVALIDITY ANALYSIS	11
A. The Scope and Content of the Prior Art	11
1. Instability of Levothyroxine Sodium Compositions	11
2. Mannitol was the Most Commonly Used Bulking Agent and was Used in Lyophilized Levothyroxine Sodium Compositions	16

3.	Mannitol’s Impact on the Stability of Lyophilized Levothyroxine Sodium Compositions was Known	18
B.	Ground 1: Claims 1–30 Would Have Been Obvious over the Abbott Label, Brower, Baheti, and Collier	21
1.	Claim 1	21
a.	It Would Have Been Obvious to Use “about 100 Micrograms of Levothyroxine Sodium”	22
b.	A POSA Would Have Been Motivated to Reduce the Amount of Mannitol Below the 10 Milligrams Used in the Abbott Label	23
(i)	Instability of Lyophilized Levothyroxine Sodium Compositions was Known	24
(ii)	Degradation of Levothyroxine Sodium by Mannitol was Known as was Reducing the Amount of Mannitol to Improve the Composition.....	24
c.	A POSA Would Have Had a Reasonable Expectation of Success.....	27
d.	Patent Owner’s Arguments during Prosecution Do Not Support Patentability	30
2.	Claims 11 and 21	38
3.	Claims 2–3, 12–13, and 22–23: Amount of Levothyroxine Sodium Converted to Liothyronine.....	39
4.	Claims 4, 14 and 24: Amount of Mannitol	43
5.	Claims 5, 15 and 25: Pharmaceutically Acceptable Liquid Carrier	44
6.	Claims 6, 16 and 26: Concentration of Levothyroxine Sodium	44
7.	Claims 7, 17 and 27: Method of Providing Levothyroxine to a Patient in Need	45
8.	Claims 8, 9, 18, 19, 28, and 29: Dosage of Levothyroxine Sodium	46

9.	Claims 10, 20, and 30: Phosphate Buffer	47
C.	Ground 2: Claims 1–30 Would Have Been Obvious over the APP Label, Brower, Baheti, and Collier.....	48
1.	Claims 1, 11, and 21	48
a.	A POSA Would Have Been Motivated to Reduce the Amount of Mannitol Below the 10 Milligram Amount Used in Conventional Compositions	49
b.	A POSA Would Have Had a Reasonable Expectation of Success.....	50
2.	Claims 2–3, 12–13, and 22–23: Amount of Levothyroxine Sodium Converted to Liothyronine.....	53
3.	Claims 4, 14, and 24: Amount of Mannitol	53
4.	Claims 5, 15 and 25: Pharmaceutically Acceptable Liquid Carrier.....	54
5.	Claims 6, 16 and 26: Concentration of Levothyroxine Sodium	54
6.	Claims 7, 17 and 27: Method of Providing Levothyroxine to a Patient in Need Thereof.....	55
7.	Claims 8, 9, 18, 19, 28, and 29: Dosage of Levothyroxine Sodium	55
8.	Claims 10, 20, and 30: Phosphate Buffer	56
D.	Ground 3: Claims 1–30 Would Have Been Obviousness over the Abbott Label, APP Label, Brower, Baheti, and Collier.....	57
1.	Claims 1, 11 and 21	57
a.	A POSA Would Have Been Motivated to Reduce the Amount of Mannitol.....	57
2.	Claims 2–3, 12–13, and 22–23: Amount of Levothyroxine Sodium Converted to Liothyronine.....	58
3.	Claims 4, 14, and 24: Amount of Mannitol	59

4.	Claims 5, 15 and 25: Pharmaceutically Acceptable Liquid Carrier	59
5.	Claims 6, 16 and 26: Concentration of Levothyroxine Sodium	60
6.	Claims 7, 17 and 27: Method of Providing Levothyroxine to a Patient in Need Thereof	61
7.	Claims 8, 9, 18, 19, 28, and 29: Dosage of Levothyroxine Sodium	61
8.	Claims 10, 20, and 30: Phosphate Buffer	62
E.	Objective Indicia of Non-Obviousness	62
1.	No Unexpected Results Over the Closest Prior Art	63
2.	Commercial Success	67
X.	CONCLUSION	67



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.